Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Work In Process: 2023-2024

Historic Work In Process for Iovance Biotherapeutics (IOVA) over the last 2 years, with Dec 2024 value amounting to $8.8 million.

  • Iovance Biotherapeutics' Work In Process rose 104.40% to $12.1 million in Q1 2025 from the same period last year, while for Mar 2025 it was $12.1 million, marking a year-over-year increase of 104.40%. This contributed to the annual value of $8.8 million for FY2024, which is 52.46% up from last year.
  • As of FY2024, Iovance Biotherapeutics' Work In Process stood at $8.8 million, which was up 52.46% from $5.7 million recorded in FY2023.
  • Over the past 5 years, Iovance Biotherapeutics' Work In Process peaked at $8.8 million during FY2024, and registered a low of $5.7 million during FY2023.
  • Its 2-year average for Work In Process is $7.3 million, with a median of $7.3 million in 2023.
  • Data for Iovance Biotherapeutics' Work In Process shows a peak YoY soared of 52.46% (in 2024) over the last 5 years.
  • Over the past 2 years, Iovance Biotherapeutics' Work In Process (Yearly) stood at $5.7 million in 2023, then spiked by 52.46% to $8.8 million in 2024.